IMRX IMRX
Company Profile ↓Company Overview
IMRX (IMRX) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -100.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -100.00% |
Stock Price Performance
| 1 Year: | +27.99% |
| 6 Months: | -10.59% |
| 3 Months: | -17.79% |
| 1 Month: | -13.92% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)46.00 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 52.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 480.83K | 682.57K | 748.20K | 660.04K | 482.13K | 183.70K | 94.42K | 38.38K | 0 | 0 | 0 | - | - | - | - | - | - | - |
| Gross Profit | - | 243.77K | 367.57K | 339.04K | 341.44K | 263.04K | 92.85K | 46.49K | 19.04K | 0 | 0 | 0 | - | - | - | - | - | - | - |
| Operating Income | - | -3.61M | -4.40M | -6.24M | -7.99M | -8.54M | -12.93M | -11.65M | -13.19M | -14.68M | -13.50M | -13.93M | -15.33M | -14.91M | -15.27M | -15.48M | -14.76M | -15.38M | -15.34M |
| Net Income | -3.20M | -3.60M | -4.40M | -6.23M | -7.99M | -8.53M | -12.90M | -11.53M | -12.84M | -13.60M | -12.19M | -12.60M | -14.31M | -14.08M | -14.60M | -15.05M | -14.43M | -14.96M | -13.46M |
| Diluted EPS | - | -0.73 | -0.89 | -1.26 | -1.61 | -0.47 | -0.49 | -0.44 | -0.49 | -0.51 | -0.43 | -0.43 | -0.49 | -0.47 | -0.49 | -0.42 | -0.40 | -0.38 | -0.21 |
| R&D Expense | - | 3.22M | 4.07M | 5.39M | 6.99M | 6.21M | 9.06M | 7.98M | 9.36M | 10.21M | 9.45M | 10.05M | 11.20M | 10.65M | 11.25M | 11.47M | 10.45M | 10.87M | 10.65M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 2.31M | 2.08M | 316.95K | 0 | - | - |
| Gross Profit | 1.03M | 926.89K | 158.83K | 0 | - | - |
| Operating Income | -17.08M | -33.89M | -51.74M | -58.41M | -64.07M | -59.38M |
| Net Income | -17.04M | -33.54M | -50.51M | -53.47M | -61.04M | -56.02M |
| Diluted EPS | -3.44 | -2.46 | -1.91 | -1.88 | -2.04 | -1.27 |
| R&D Expense | 15.00M | 26.54M | 36.27M | 41.62M | 47.96M | 42.05M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 38.42M | 166.70M | 122.37M | 102.58M | 52.71M | 231.99M |
| Total Equity | -6.53M | -22.48M | 155.98M | 109.85M | 90.58M | 41.39M | 218.48M |
| Cash & Equivalents | - | 37.09M | 74.89M | 72.64M | 59.41M | 36.14M | 128.65M |
| Total Liabilities | - | 2.80M | 10.72M | 12.52M | 12.01M | 11.33M | 13.50M |
| Current Liabilities | - | 2.26M | 5.63M | 8.05M | 7.85M | 7.50M | 10.07M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -14.62M | -30.85M | -44.10M | -48.97M | -55.00M | -45.34M |
| Investing Cash Flow | -53.41K | -75.62M | 41.83M | 7.30M | 26.43M | -88.74M |
| Financing Cash Flow | 37.98M | 144.26M | 19.00K | 28.44M | 5.30M | 226.58M |
| Capital Expenditure | -53.41K | -60.79K | -742.48K | -342.75K | -84.88K | -142.23K |
| Free Cash Flow | -14.67M | -30.91M | -44.84M | -49.31M | -55.08M | -45.49M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | 44.6% | 44.6% | 50.1% | - | - | - |
| Operating Margin % | -739.0% | -1,629.2% | -16,325.8% | - | - | - |
| Net Margin % | -737.2% | -1,612.3% | -15,937.3% | - | - | - |
| ROE % | 75.8% | -21.5% | -46.0% | -59.0% | -147.5% | -25.6% |
| ROCE % | -47.2% | -21.0% | -45.3% | -61.7% | -141.7% | -26.8% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IMRX
Immuneering Q2 Loss Widens as Cash Runway Extends Into 2029 - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxQLXJGLUF3RTFZSm5uLXpyb05iTGQxcVVnRmlPSVJNMEVVVkdNSjhJa1hmckNPaUlhRS1kY2dreHkwN294S2FBOUpBTmxnVWpOVFRXbXFKNkVQd3FTbjEwUGpLWmRrb21PdnZEVHBqcUxzR3Y0T1hBaEY5dUZRN2RRVUQ3dVVLUnVMN1dabE…
Pancreatic cancer trial tests atebimetinib combo, results expected mid-2028 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxOT3NsT0xSN2stdTA3aWxkX1hJQlhQXzRLbGlKQW9sbW83amdjUUlNdzdvQ2g1cFlLZEpaazdCYUUwM0ttSExyWmNNRVBEMlhLdk05NDZUM21NcnoydWJITmp6N3p0NEs0TG05WWxJWHRlNjZSNy16OHNWZWx4RFh4M1pOVDZfYl9BeVE3OV…
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPbE5Rbm44YWlxRTRycS0wenZfaFlhMEVyb1ZHS3JzOHdET0tmSFJhUThkYU8xLThHU2hpbXJMeDcwOGp0YnVlTUcwQWVoMThXRUxwQTVySTJ5Y3E1R3E5OTVEdURhY3dyTWpkN0xDMlRxWGZmNXdoTDFyTTZyS1ljVTNlOFgwdHZBSHBEV2…
Immuneering Releases Q2 2026 Financial Results - AlphaStreet
<a href="https://news.google.com/rss/articles/CBMiggFBVV95cUxQWElMYWJPb2VOMktzTXdkcDZEMVNXUS1lbXVhQ3IySkVMYkt6b2hIcGs1dVYxZE1zMmZUUGd2bHc4TEZDSWZnazlBc1pROHkwaGxCME9yQlUzRVhWbGszaEZINzVPc1VkcEkzcDhIbHgyUDUxVmdTOEE0VlNweGg0Q1Zn0gGCAUFVX3lxTF…
IMRX Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE5zOVNaRlRoeWtqNFlIeE85cXltWW1JSFJWUW1PdlZtanhzUW1KdGtTVUNDemZZRHB0QzJtNlZKVXVKbjd2SVR2eURrOXZROUxXX2Jwc0FIeTRMSzA5aXV3UHd0cm9vNmhQRVd5MEJjclljU1FCLWZPY2J3?oc=5" target="_blank">IMR…
IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxNcUJRS19FRkZQU05GVWo0LXlDeFIyejdMc2lUWjlKQ2JVM1dHdXg4Mll2U1AtUDhWdjNnLUllTUFER1NKTXVhRnhqa2NfV1J3OW9vZkZaNXJCZDBVampsVDFCZkk2T2w0SjR2NG9LQ1FndFZKZ29WQUV4Z0RnZmZTYVhsN29Kc19iNGZQbm…
IMRX — Frequently Asked Questions
What is the current share price of IMRX?
As of 2026-08-05 17:25 PDT, IMRX trades at $4.39 on NASDAQ/NYSE. Its 52-week range is $3.04 to $9.26.
What is the P/E ratio of IMRX?
IMRX trades at a trailing price-to-earnings (P/E) ratio of -3.46.
What is the return on equity (ROE) of IMRX?
IMRX has a return on equity (ROE) of -25.64%. Its return on capital employed (ROCE) is -26.76%.
Is IMRX a good stock to buy?
This page provides a data-driven analysis of IMRX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.